[1] Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127:2672–81.
[2] Morimoto A, Oh Y, Shioda Y, et al. Recent advances in langerhans cell histiocytosis. Pediatr Int. 2014;56:451–61.
[3] Berres ML, Merad M, Allen CE. Progress in understanding the pathogenesis of langerhans cell histiocytosis: back to histiocytosis X?. Br J Haematol. 2015;169:3–13.
[4] Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem langerhans’ cell histiocytosis. J Pediatr. 2001;138:728–34.
[5] Gadner H, Grois N, Pötschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008;111:2556–62.
[6] Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121:5006–14.
[7] Morimoto A, Ikushima S, Kinugawa N, et al. Improved outcome in the treatment of pediatric multifocal langerhans cell histiocytosis: results from the Japan Langerhans cell histiocytosis study group-96 protocol study. Cancer. 2006;107:613–9.
[8] Morimoto A, Shioda Y, Imamura T, et al. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem langerhans cell histiocytosis: results of the Japan langerhans cell histiocytosis study group-02 protocol study. Int J Hematol. 2016;104:99–109.
[9] Morimoto A, Shioda Y, Imamura T, et al. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan langerhans cell histiocytosis study group-02 protocol study. Int J Hematol. 2018;108:192–8.
[10] Minkov M, Steiner M, Pötschger U, et al. Reactivations in multisystem langerhans cell histiocytosis: data of the international LCH registry. J Pediatr 2008;153:700–5, 705.e1, 705:e701–e702.
[11] Sakamoto K, Morimoto A, Shioda Y, et al. Central diabetes insipidus in pediatric patients with langerhans cell histiocytosis: results from the JLSG-96/02 studies. Pediatr Blood Cancer. 2018:e27454.
[12] Sakamoto K, Morimoto A, Shioda Y, et al. Long-term complications in uniformly treated paediatric langerhans histiocytosis patients disclosed by 12 years of follow-up of the JLSG-96/02 studies. Br J Haematol. 2021;192:615–20.
[13] Zinn DJ, Grimes AB, Lin H, et al. Hydroxyurea: a new old therapy for langerhans cell histiocytosis. Blood. 2016;128:2462–5.
[14] Morimoto A, Shioda Y, Imamura T, et al. Nationwide survey of bisphosphonate therapy for children with reactivated langerhans cell histiocytosis in Japan. Pediatr Blood Cancer. 2011;56:110–5.
[15] De Benedittis D, Mohamed S, Rizzo L, et al. Indomethacin is an effective treatment in adults and children with bone langerhans cell histiocytosis (LCH). Br J Haematol. 2020;191:e109–13.
[16] Taniguchi M, Sakamoto K, Shioda Y, et al. Salvage therapy with 2-chlorodeoxyadenosine for refractory and relapsed pediatric langerhans cell histiocytosis: an updated nationwide survey in Japan. Int J Hematol. 2021;113:461–3.
[17] Simko SJ, Tran HD, Jones J, et al. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including langerhans cell histiocytosis, juvenile xanthogranuloma and rosai-dorfman disease. Pediatr Blood Cancer. 2014;61:479–87.
[18] Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005;106:2269–75.
[19] Wang WC, Helms RW, Lynn HS, et al. Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS study. J Pediatr. 2002;140:225–9.
[20] Joseph L, Jean C, Manceau S, et al. Effect of hydroxyurea exposure before puberty on sperm parameters in males with sickle cell disease. Blood. 2021;137:826–9.
論文の公開元へ
